Frontlight ResearchEarly access
Myelodysplastic syndromes trials in United States
224 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleIdentify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
- Where
- Allentown, Hartford, New York
- Age
- 18 years to 80 years
- People
- 1,365
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT02677064 - Phase 2Taking peopleStatins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
- Where
- St Louis
- Age
- 18 years and over
- People
- 16
- Run by
- Washington University School of Medicine
See details and how to joinNCT05483010 - Phase 2Taking peopleCombination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Where
- Seattle
- Age
- 18 years and over
- People
- 20
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT07046078 - Phase 2Taking peopleCladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- Where
- Houston
- Age
- 60 years and over
- People
- 160
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT01515527 - No phaseTaking peopleGenomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
- Where
- Albany, Boston, Burlington, Hartford, Lebanon, Portland, Providence
- Age
- Up to 30 years
- People
- 300
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT04968834 - Phase 1Taking peopleTagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
- Where
- Duarte
- Age
- 18 years to 75 years
- People
- 43
- Run by
- City of Hope Medical Center
See details and how to joinNCT06498973 - Phase 1Taking peopleHM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Where
- Minneapolis
- Age
- 18 years and over
- People
- 45
- Run by
- Masonic Cancer Center, University of Minnesota
See details and how to joinNCT06594445 - No phaseTaking peopleCD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Where
- Philadelphia
- Age
- Up to 25 years
- People
- 50
- Run by
- Children's Hospital of Philadelphia
See details and how to joinNCT03810196 - Phase 2Taking peopleTrial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Where
- Hackensack, Los Angeles, Nashville, New York, Portland, Tampa
- Age
- 18 years and over
- People
- 80
- Run by
- Orca Biosystems, Inc.
See details and how to joinNCT07216443 - Phase 2Taking peopleAllo HSCT Using RIC and PTCy for Hematological Diseases
- Where
- Minneapolis
- Age
- Up to 75 years
- People
- 56
- Run by
- Masonic Cancer Center, University of Minnesota
See details and how to joinNCT05805605 - Phase 3CompletedA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Boston, Chicago, Cleveland, Detroit, Houston, Los Angeles, Nashville, New York, Oakland, Philadelphia, Stanford, Tampa
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 1Taking peopleIadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- Where
- Portland
- Age
- 18 years and over
- People
- 30
- Run by
- OHSU Knight Cancer Institute
See details and how to joinNCT06357182 - No phaseTaking peopleRegistry of Older Patients With Cancer
- Where
- Boone, Chapel Hill, Greenville, Hendersonville, Morehead City, New Bern, Raleigh
- Age
- 65 years and over
- People
- 3,000
- Run by
- UNC Lineberger Comprehensive Cancer Center
See details and how to joinNCT01137825 - Phase 2Taking peopleVedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- Where
- Duarte
- Age
- 18 years to 80 years
- People
- 35
- Run by
- City of Hope Medical Center
See details and how to joinNCT06815003 - Phase 2Taking peopleIntensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
- Where
- Chicago
- Age
- 18 years to 65 years
- People
- 38
- Run by
- University of Illinois Chicago
See details and how to joinNCT06802315 - Phase 2Taking peopleMyeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Where
- Minneapolis
- Age
- Up to 60 years
- People
- 300
- Run by
- Masonic Cancer Center, University of Minnesota
See details and how to joinNCT03314974 - Phase 1/2Taking peopleStudy to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Where
- Atlanta, Bethesda, Indianapolis, Omaha, Philadelphia
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- CellCentric Ltd.
See details and how to joinNCT04068597 - Phase 1Taking peopleTrial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
- Where
- Palo Alto
- Age
- 18 years to 70 years
- People
- 24
- Run by
- Stanford University
See details and how to joinNCT06551584 - Phase 2Taking peopleMethylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- Where
- Houston
- Age
- 18 years and over
- People
- 140
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT01624805 - Phase 1/2Taking people211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Where
- Seattle
- Age
- 18 years to 75 years
- People
- 75
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT03128034 - Phase 1/2Taking people211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Where
- Seattle
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT03670966 - Phase 1Taking peopleOnvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
- Where
- Rochester
- Age
- 18 years and over
- People
- 25
- Run by
- Mayo Clinic
See details and how to joinNCT05549661 - No phaseTaking peopleFamilial Investigations of Childhood Cancer Predisposition
- Where
- Memphis
- People
- 1,500
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT03050268 - Phase 1Taking peopleSL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Where
- Boston, Duarte, Houston
- Age
- 18 years and over
- People
- 72
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT03113643 - Phase 1Taking peopleA Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Where
- Boston
- Age
- 12 years and over
- People
- 50
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT04024761